NASDAQ:ISEE IVERIC bio - ISEE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $23.48 -0.33 (-1.39%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$23.43▼$24.0950-Day Range$18.96▼$24.5652-Week Range$8.85▼$26.35Volume2.19 million shsAverage Volume2.53 million shsMarket Capitalization$3.22 billionP/E RatioN/ADividend YieldN/APrice Target$27.30 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media IVERIC bio MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside16.3% Upside$27.30 Price TargetShort InterestBearish7.35% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 4 Articles This WeekInsider TradingSelling Shares$1.39 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.68) to ($1.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.48 out of 5 starsMedical Sector904th out of 983 stocksPharmaceutical Preparations Industry438th out of 478 stocks 2.4 Analyst's Opinion Consensus RatingIVERIC bio has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.30, IVERIC bio has a forecasted upside of 16.3% from its current price of $23.48.Amount of Analyst CoverageIVERIC bio has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.35% of the outstanding shares of IVERIC bio have been sold short.Short Interest Ratio / Days to CoverIVERIC bio has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in IVERIC bio has recently increased by 5.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIVERIC bio does not currently pay a dividend.Dividend GrowthIVERIC bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ISEE. Previous Next 3.0 News and Social Media Coverage News SentimentIVERIC bio has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for IVERIC bio this week, compared to 2 articles on an average week.Search Interest67 people have searched for ISEE on MarketBeat in the last 30 days. This is an increase of 570% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added IVERIC bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IVERIC bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,393,904.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of IVERIC bio is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IVERIC bio are expected to grow in the coming year, from ($1.68) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IVERIC bio is -15.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IVERIC bio is -15.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIVERIC bio has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IVERIC bio (NASDAQ:ISEE) StockIVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.Read More Receive ISEE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ISEE Stock News HeadlinesMarch 18, 2023 | nasdaq.comGuru Fundamental Report for ISEEMarch 12, 2023 | americanbankingnews.comIVERIC bio (NASDAQ:ISEE) vs. Kezar Life Sciences (NASDAQ:KZR) Head to Head ContrastMarch 21, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 3, 2023 | finance.yahoo.comIVERIC bio, Inc. (NASDAQ:ISEE) Q4 2022 Earnings Call TranscriptMarch 2, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Seagen (SGEN) and IVERIC bio (ISEE)March 2, 2023 | finance.yahoo.comQ4 2022 IVERIC bio Inc Earnings CallMarch 1, 2023 | finance.yahoo.comIVERIC Bio (ISEE) Q4 2022 Earnings Call TranscriptMarch 1, 2023 | finance.yahoo.comIVERIC bio's Geographic Atrophy Candidate Shows Significant Reduction In Disease ProgressionMarch 21, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 1, 2023 | finance.yahoo.comIveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER TrialsMarch 1, 2023 | finance.yahoo.comIveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial ResultsFebruary 28, 2023 | finance.yahoo.comIveric Bio to Present at the Cowen 43rd Annual Health Care ConferenceFebruary 22, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on IVERIC bio (ISEE)February 22, 2023 | finance.yahoo.comIveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023February 17, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on IVERIC bio (ISEE)February 16, 2023 | finance.yahoo.comIveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic AtrophyJanuary 24, 2023 | finance.yahoo.comInsiders who bought IVERIC bio, Inc. (NASDAQ:ISEE) last year must be regretting not buying more as market cap hits US$2.8bJanuary 3, 2023 | finance.yahoo.comRTP gene therapy startup expands pipeline through deal with public biotechJanuary 3, 2023 | finance.yahoo.comIveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of DirectorsDecember 20, 2022 | markets.businessinsider.comIVERIC Bio Completes Rolling NDA Submission For Avacincaptad Pegol - Quick FactsDecember 20, 2022 | finance.yahoo.comIveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic AtrophyDecember 7, 2022 | seekingalpha.comIveric bio: Building Momentum Around Zimura, Rate BuyNovember 18, 2022 | msn.comWhy Farfetch Shares Are Trading Lower; Here Are 26 Stocks Moving PremarketNovember 18, 2022 | marketwatch.comIveric bio Shares Rally Premarket on FDA Breakthrough Designation >ISEENovember 18, 2022 | finance.yahoo.comIveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic AtrophyNovember 18, 2022 | finance.yahoo.comIVERIC bio Secures Breakthrough Therapy Tag For Its Flagship Geographic Atrophy CandidateNovember 4, 2022 | finance.yahoo.comIveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic AtrophySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ISEE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ISEE Company Calendar Last Earnings3/01/2023Today3/21/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ISEE CUSIPN/A CIK1410939 Webivericbio.com Phone(609) 474-6755FaxN/AEmployees94Year FoundedN/APrice Target and Rating Average Stock Price Forecast$27.30 High Stock Price Forecast$35.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+16.3%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.16% Return on Assets-44.33% Debt Debt-to-Equity Ratio0.18 Current Ratio18.63 Quick Ratio18.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.43 per share Price / Book5.30Miscellaneous Outstanding Shares137,120,000Free Float133,420,000Market Cap$3.22 billion OptionableOptionable Beta1.09 Key ExecutivesGlenn P. SblendorioChief Executive Officer & DirectorPravin U. DugelPresident & DirectorKeith WestbyChief Operating Officer & Senior Vice PresidentDavid F. CarrollChief Financial Officer, Treasurer & Senior VPXiao Ping DaiChief Technical OfficerKey CompetitorsAmicus TherapeuticsNASDAQ:FOLDACADIA PharmaceuticalsNASDAQ:ACADPTC TherapeuticsNASDAQ:PTCTReata PharmaceuticalsNASDAQ:RETAZai LabNASDAQ:ZLABView All CompetitorsInsiders & InstitutionsKeith WestbySold 20,000 sharesTotal: $478,600.00 ($23.93/share)Voya Investment Management LLCBought 171,434 shares on 2/28/2023Ownership: 0.309%Parallax Volatility Advisers L.P.Sold 5,300 shares on 2/27/2023Ownership: 0.000%Keith WestbySold 15,000 sharesTotal: $375,750.00 ($25.05/share)Alliancebernstein L.P.Bought 1,870,847 shares on 2/16/2023Ownership: 3.506%View All Insider TransactionsView All Institutional Transactions ISEE Stock - Frequently Asked Questions Should I buy or sell IVERIC bio stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ISEE shares. View ISEE analyst ratings or view top-rated stocks. What is IVERIC bio's stock price forecast for 2023? 9 brokers have issued 12-month price targets for IVERIC bio's stock. Their ISEE share price forecasts range from $18.00 to $35.00. On average, they expect the company's share price to reach $27.30 in the next year. This suggests a possible upside of 16.3% from the stock's current price. View analysts price targets for ISEE or view top-rated stocks among Wall Street analysts. How have ISEE shares performed in 2023? IVERIC bio's stock was trading at $21.41 on January 1st, 2023. Since then, ISEE stock has increased by 9.7% and is now trading at $23.48. View the best growth stocks for 2023 here. Are investors shorting IVERIC bio? IVERIC bio saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 10,080,000 shares, an increase of 5.9% from the February 13th total of 9,520,000 shares. Based on an average daily volume of 2,450,000 shares, the short-interest ratio is currently 4.1 days. View IVERIC bio's Short Interest. When is IVERIC bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our ISEE earnings forecast. How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:ISEE) issued its quarterly earnings data on Wednesday, March, 1st. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.10. During the same period in the previous year, the company earned ($0.29) earnings per share. What ETFs hold IVERIC bio's stock? ETFs with the largest weight of IVERIC bio (NASDAQ:ISEE) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), American Century Mid Cap Growth Impact (MID), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), Harbor Health Care ETF (MEDI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What is Glenn Spina's approval rating as IVERIC bio's CEO? 6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC). What is IVERIC bio's stock symbol? IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE." Who are IVERIC bio's major shareholders? IVERIC bio's stock is owned by many different institutional and retail investors. Top institutional investors include Avoro Capital Advisors LLC (5.59%), Price T Rowe Associates Inc. MD (4.01%), Alliancebernstein L.P. (3.51%), Braidwell LP (2.77%), Point72 Asset Management L.P. (2.46%) and Deutsche Bank AG (2.01%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel. View institutional ownership trends. How do I buy shares of IVERIC bio? Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IVERIC bio's stock price today? One share of ISEE stock can currently be purchased for approximately $23.48. How much money does IVERIC bio make? IVERIC bio (NASDAQ:ISEE) has a market capitalization of $3.22 billion. The company earns $-185,210,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. How can I contact IVERIC bio? IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com. This page (NASDAQ:ISEE) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.